

IVUS: Pre-Intervention Assessment and Optimizing Final Result

Gary S. Mintz, MD

**Cardiovascular Research Foundation
New York, NY**



**COLUMBIA UNIVERSITY
MEDICAL CENTER**

Most of the concepts used in IVUS-guided intervention are no different from those used in angiography-guided intervention. However, unlike angiography, IVUS is actually able to make precise measurements and assess lesion morphology.


- Weigh potential problems (i.e. LM disease, significant proximal or distal disease)
- Assess lesion severity
- Assess unusual lesion morphology (i.e., aneurysms, calcium, thrombi, in-stent restenosis, etc.)
- Measure vessel size
- Measure lesion length
- Determine and fine-tune the final result of interventions
- Assess complications



Validation of IVUS assessment of ischemia-producing stenoses (Doppler FloWire, SPECT, and Pressure Wire)

	IVUS MLA ≥4.0mm ²	IVUS MLA <4.0mm ²
CFR < 2.0	2	27
CFR ≥ 2.0	39	4
<i>Diagnostic accuracy = 92%.</i> <i>Abizaid et al. Am J Cardiol 1998;82:42-8</i>		
	IVUS MLA ≥4.0mm ²	IVUS MLA <4.0mm ²
+ Spect	4	42
- Spect	20	1

Diagnostic accuracy = 93%.
Nishioka et al. J Am Coll Cardiol 1999;33:1870-8



*Takagi, et al. Circulation
1999; 100:250-5*

Clinical follow-up in 357 intermediate lesions in 300 pts with deferred intervention after IVUS imaging



- Death/MI/TLR @ (mean) 13 mos = 8% overall (2% death/MI and 6% TLR)
- Death/MI/TLR @ (mean) 13 mos = 4.4% in lesions with $\text{MLA} > 4.0 \text{ mm}^2$
- Only independent predictor of death/MI/TLR was IVUS MLA ($p=0.0041$)
- Independent predictors of TLR were DM ($p=0.0493$) and IVUS MLA ($p=0.0042$)

IVUS Criteria for a ‘Significant’ Stenosis


- Based on the studies comparing IVUS to flow wire, pressure wire, or SPECT thallium and based on studies with clinical outcome - most feel that a lumen area greater than 4.0mm^2 in a proximal epicardial artery excluding the Left Main (and SVGs) is the criterion to defer an intervention

9-month minimum lumen area that predicts 3-year MACE-free survival in patients from TAXUS IV, V, and VI

n=348	BMS	
	C-statistic	Cutoff
Minimum lumen area	0.73	4.0mm ²
n=351	Taxus	
	C-statistic	Cutoff
Minimum lumen area	0.75	4.2mm ²


Of all the coronary segments, the LM has the greatest angiographic variability - I

Comparison between percent stenosis assessment from the quality control (QC) lab vs the clinical site in the CASS Study



*area of the square is proportional to the number of cases



Of all the coronary segments, the LM has the greatest angiographic variability - II




But surely we are better today!

- 51 intermediate or equivocal LM lesions were evaluated by FFR and angiography. Four experienced interventional cardiologists visually classified lesions as 'significant', 'not significant', or 'unsure.'
- The 4 experienced interventional cardiologists achieved correct lesion classification in no more than ~50% of each case regardless of the FFR threshold (≤ 0.75 or ≤ 0.80).
- Interobserver variability was large, resulting in unanimous correct lesion classification in only 29%!


Follow-up of 122 patients with moderate LM disease



Independent predictors of MACE
@11.7 months: DM ($p=0.004$),
untreated lesion $>50\%$ ($p=0.037$),
and IVUS MLD ($p=0.005$) – but
NOT the plaque burden.



IVUS determinants of LMCA FFR <0.75





IVUS assessment of LM disease significance is based on lumen dimensions, not plaque burden



Plaque burden (P&M/EEM) = 68%
MLA=7.2mm²

Which of these LMCA lesions is significant and, therefore, should be treated? And which is not??







0 → 1.5 → 6.0mm




0 → 3.0 → 9.0mm





0 → 2.0 → 8.0mm




0 → 1.0 → 4.0mm

IVUS Criteria for a ‘Significant’ LMCA Stenosis

- Most IVUS LMCA studies show either insignificant disease or critical disease
- Absolute lumen CSA <6.0mm² (or MLD <3.0mm) is the suggested criterion for a significant LMCA stenosis
 - Correlates with a LMCA FFR<0.75
 - Murray’s Law ($LMCAr^3 = LADr^3 + LCXr^3$)
 - Does not depend on finding a disease-free reference segment
- It is not clear whether the same criteria should be used for ostial LM lesions as for mid-shaft/distal bifurcation lesions and for positively vs negatively remodeled lesions

Unusual Lesions


- Filling Defects
- Aneurysms
- Acute Coronary Syndromes
- Spontaneous Dissections
- Hazy Lesions



CARDIOVASCULAR
RESEARCH
FOUNDATIONS



COLUMBIA UNIVERSITY
MEDICAL CENTER





CARDIOVASCULAR
RESEARCH
FOUNDATION



COLUMBIA UNIVERSITY
MEDICAL CENTER

Attenuated Plaque




0 → 1.5 → 9.0mm



0

4mm



4mm



CARDIOVASCULAR
RESEARCH
FOUNDATION



COLUMBIA UNIVERSITY
MEDICAL CENTER



0 → 8

→ 40mm



CARDIOVASCULAR
RESEARCH
FOUNDATION



COLUMBIA UNIVERSITY
MEDICAL CENTER

IVUS Classification of Angiographic Aneurysms

- Of 77 angiographic aneurysms
 - 21 (27%) true aneurysm
 - 3 (4%) pseudoaneurysm
 - 12 (16%) complex plaques or unhealed dissections
 - 41 (53%) normal segment adjacent to one or more stenoses

	True Aneurysm	PSA	Complex Plaque	Normal Site with Adjacent Stenoses
No prior PCI	10	0	6	26
Prior PCI	11	3	6	15







Pre-, Inter-, and Post-Procedure IVUS



- Pre-intervention
 - Measure vessel size and lesion length to select DES size and length
 - Assess unusual lesion morphology
- Post-intervention
 - Expansion*: Absolute stent CSA or stent CSA relative to a pre-defined reference or target area/diameter
 - Apposition*: Contact between stent and vessel wall
 - Full lesion coverage
 - Complications

***While expansion and apposition can co-exist, they not the same.
The prognostic implications are different, and the solutions are
different. These terms should NOT be used interchangeably**


IVUS vs QCA measurements of reference lumen dimensions (3311 nonostial lesions)



IVUS vs QCA measurement of lesion length




IVUS-QCA length=
 $0.6 \pm 7.2\text{mm}$



Predictors of DES



	DES Thrombosis	DES Restenosis
Underexpansion	<ul style="list-style-type: none">• Fujii et al, <i>J Am Coll Cardiol</i> 2005;45:995-8)• Okabe et al, <i>Am J Cardiol</i> 2007;100:615-20• Liu et al, <i>JACC Cardiovasc Interv</i>, 2009;2:428-34	<ul style="list-style-type: none">• Sonoda et al, <i>J Am Coll Cardiol</i> 2004;43:1959-63• Hong et al, <i>Eur Heart J</i> 2006;27:1305-10• Doi et al, <i>JACC Cardiovasc Interv</i>, <i>in press</i>• Fujii et al, <i>Circulation</i> 2004;109:1085-1088
Edge problems (geographic miss, secondary lesions, large plaque burden, etc)	<ul style="list-style-type: none">• Fujii et al, <i>J Am Coll Cardiol</i> 2005;45:995-8)• Okabe et al, <i>Am J Cardiol</i> 2007;100:615-20	<ul style="list-style-type: none">• Sakurai et al, <i>Am J Cardiol</i> 2005;96:1251• Liu et al, <i>Am J Cardiol</i> 2009;103:501-6• Costa et al, <i>Am J Cardiol</i>, 2008;101:1704-11

Cypher in SIRIUS



**By definition,
sensitivity/specificity curve
analysis "must" identify a
single MSA that best
separates restenosis from
no restenosis.**


Cypher at AMC



(Sonoda et al. J Am Coll Cardiol 2004;43:1959-63)
(Hong et al. Eur Heart J 2006; 27: 1305-10)
(Doi et al. JACC Cardivasc Interv, in press)





“Optimal” MSA and TLR after LMCA DES Implantation (n=595)





Manufacturer's Compliance Charts Cannot Be Used to Guarantee Adequate Stent Expansion

Comparison of IVUS-measured minimum stent diameter (MSD) and minimum stent area (MSA) with the predicted measurements from Cordis (Cypher in yellow, n=133) and BSC (Taxus in red, n=67). DES achieve an average of only 75% of the predicted MSD (66% of MSA)



Comparison of 9-month QCA edge restenosis vs reference lumen area and plaque burden in TAXUS-IV, V, and VI (n=810)






CARDIOVASCULAR
RESEARCH
FOUNDATION



COLUMBIA UNIVERSITY
MEDICAL CENTER

Perforation



CARDIOVASCULAR
RESEARCH
FOUNDATION



COLUMBIA UNIVERSITY
MEDICAL CENTER